Jason Adair Sells 1,189 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) insider Jason Adair sold 1,189 shares of the stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $14.58, for a total transaction of $17,335.62. Following the sale, the insider now directly owns 111,537 shares of the company’s stock, valued at $1,626,209.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jason Adair also recently made the following trade(s):

• On Monday, March 18th, Jason Adair sold 4,657 shares of Liquidia stock. The shares were sold at an average price of $15.81, for a total transaction of $73,627.17.

Liquidia Stock Performance

Shares of NASDAQ:LQDA opened at $13.68 on Tuesday. The firm has a 50 day simple moving average of $14.77 and a 200 day simple moving average of $10.88. Liquidia Co. has a 52 week low of $5.71 and a 52 week high of $16.99. The company has a market cap of $1.04 billion, a PE ratio of -11.40 and a beta of 0.16.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Wednesday, March 13th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.19). Liquidia had a negative return on equity of 132.16% and a negative net margin of 448.89%. The business had revenue of $4.53 million for the quarter, compared to analyst estimates of $5.29 million. On average, equities analysts predict that Liquidia Co. will post -0.98 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD increased its stake in shares of Liquidia by 9.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,342 shares of the company’s stock worth $137,000 after purchasing an additional 989 shares during the last quarter. SkyView Investment Advisors LLC grew its stake in Liquidia by 1.4% in the 4th quarter. SkyView Investment Advisors LLC now owns 111,571 shares of the company’s stock valued at $1,342,000 after buying an additional 1,571 shares during the last quarter. BNP Paribas Arbitrage SNC grew its stake in Liquidia by 20.5% in the 1st quarter. BNP Paribas Arbitrage SNC now owns 9,993 shares of the company’s stock valued at $69,000 after buying an additional 1,702 shares during the last quarter. Chartwell Investment Partners LLC grew its stake in Liquidia by 6.0% in the 4th quarter. Chartwell Investment Partners LLC now owns 31,024 shares of the company’s stock valued at $197,000 after buying an additional 1,769 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Liquidia by 7.1% in the 4th quarter. JPMorgan Chase & Co. now owns 27,923 shares of the company’s stock valued at $178,000 after buying an additional 1,845 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Analysts Set New Price Targets

LQDA has been the subject of several recent research reports. Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of Liquidia in a research note on Wednesday, April 10th. Bank of America increased their target price on shares of Liquidia from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, December 21st. LADENBURG THALM/SH SH upped their price target on shares of Liquidia from $15.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, December 21st. Wedbush restated an “underperform” rating and issued a $3.00 price target on shares of Liquidia in a research report on Thursday, December 21st. Finally, HC Wainwright upped their price target on shares of Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, March 14th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $21.00.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).